07 Jun 2021 OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
06 Jun 2021 Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
04 Jun 2021 Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
04 Jun 2021 Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
04 Jun 2021 Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
04 Jun 2021 Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
02 Jun 2021 AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
01 Jun 2021 Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
27 May 2021 Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
26 May 2021 Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
26 May 2021 OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
26 May 2021 Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University
26 May 2021 Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
21 May 2021 Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
20 May 2021 Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data
20 May 2021 Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
18 May 2021 Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
18 May 2021 Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
17 May 2021 AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
17 May 2021 Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
12 May 2021 INOVIO’s Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against major viral variants in preclinical studies
12 May 2021 Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19
11 May 2021 Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
10 May 2021 INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
08 May 2021 Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up